Drug reduces invasive disease toll in high-risk early breast cancer: study
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
Combining abemaciclib with endocrine therapy gives better odds of invasive disease-free survival in people with high-risk early breast cancer, researchers report.
In the phase 3 MonarchE trial, more than 5600 people with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative disease judged to be at high risk of recurrence were randomised to abemaciclib (150mg, twice daily for two years) plus endocrine therapy or endocrine therapy alone (without placebo).
Results of a pre-planned efficacy interim analysis at 323 invasive disease-free survival events were presented at the European Society for Medical Oncology (ESMO) virtual congress 2020 by Professor Stephen Johnston of Royal Marsden Hospital, UK.
